PI Industries to Foray into Pharma Sector and Acquire – Ind-Swift to Sell API business

Ind-Swift Laboratories will sell its Active Pharmaceutical Ingredients (API) business to PI Industries for an enterprise value of Rs 1,530 crore.

The sale is expected to close on October 21, 2021, subject to approvals and closing conditions.

Ind-Swift Laboratories + PI Industries

In a press release, the pharmaceutical company intimated the sale has been approved by its board of directors on July 30 and will be completed on shareholder approvals.

The API business had a turnover of Rs 856.58 crore for FY21, constituting 100 percent of the company’s consolidated revenue for the fiscal. Its net worth is Rs 289.99 crore as of March 2021.

The sale is expected to close on October 21, 2021, subject to approvals and closing conditions. “The company will intimate the stock exchanges once the sale is completed,” the release added.

The company said rationale for the slump sale is to raise funds, facilitate repayment of all existing debt exposure and making Ind-Swift debt free, and utilising surplus funds for strategic investments and acquisitions to enhance stakeholder value in the long run.

PI Industries is a BSE and NSE listed company based in Udaipur, Rajasthan. It is not part of the promoter or promoter group or group companies of the company (Ind-Swift) and there will be no change on the shareholding of the listed entity.

Related posts

November 2024 || New ISO Published || β-sitosterol Steroid Fungicide- Shaanxi Sunger Road Bio-Science

Global Keysight Analysis on Syngenta’s Patent Declarations in China for Benzovindiflupyr and Pydiflumetofen Fungicides

Indian Pesticide Approval Minutes: Insights from the 459th Registration Meeting